Drug Development · global
Tau-targeting Alzheimer’s drug reports two-year data showing 38% slower cognitive and functional decline
The Phase 2 extension study of diranersen showed signals of sustained slowing of decline, but the two-year comparison took place in the open-label phase. Whether efficacy can be established remains a question for confirmatory trials.
For patients with early Alzheimer’s disease, an important treatment goal is to slow the loss of memory and the ability to carry out daily activities. Biogen announced on November 17 that its investigational tau-targeting drug diranersen showed signals of slowing decline over two years of follow-up in the Phase 2 CELIA study. However, these results come from an extension study, and the strength of the evidence remains limited by the comparison used.
According to Biogen’s announcement, the group receiving 60 milligrams every six months had 38% less decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at week 96 than the comparison group, with a difference of 1.09 points between the groups. This scale assesses both cognition and daily functioning; the 38% refers to a relative reduction in the extent of score worsening, not a recovery of the same proportion of patients’ abilities.
In an announcement on the same day, co-developer Ionis added that the analysis compared 60 participants who continued receiving the above dose with 115 participants initially randomized to placebo. By week 96, after entering the extension phase, participants in the original placebo group had either not yet received diranersen or had received only one dose. These are therefore not results from a study that remained double-blind and placebo-controlled throughout the two years, nor can they be directly viewed as a comparison between continuous treatment and no treatment at all.
Data presented at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference also showed signals of slower decline on other assessments: 54% on the ADAS-Cog13 cognitive scale, 30% on the ADCS-ADL-MCI daily functioning scale, and 46% on the modified iADRS composite measure of cognition and function. The company said the relative slowing on five of six measures was greater than at week 76. However, the scales measure different abilities, so these percentages cannot be treated as interchangeable measures of efficacy.
Diranersen, also known as BIIB080 or IONIS-MAPTrx, is an antisense oligonucleotide that reduces tau production by acting on the MAPT messenger RNA needed to produce the tau protein. This approach seeks to intervene in the disease at the protein production stage. CELIA enrolled 416 patients with early disease. The original placebo-controlled treatment period was 18 months, and the primary endpoint was the dose response in CDR-SB change at week 76.
On safety, the two companies said no new safety signals had been identified through two years of follow-up. This does not mean there were no side effects, nor is it sufficient to rule out less common or longer-term risks. Continued follow-up remains an important part of determining whether this type of treatment can be used over the long term.
These data provide another clinical clue for the tau-lowering treatment strategy, but they do not yet establish that benefits increase over two years. The comparison during the open-label extension phase, the composition of participants who remained in the study, and the initiation of treatment in the original placebo group all affect interpretation. Diranersen remains an investigational therapy, and its efficacy and risks require further validation in confirmatory studies.